News

The drugstore has already switched to the longer opening hours at eight of its stores; the two most recent changes being made in Oxford and Milton Keynes at

The alliance combines Sirna’s extensive expertise in short interfering RNA (siRNA) chemistry and biology with GSK’s industry leading capabilities in the development and commercialization of novel therapies for

The findings, reported at the annual meeting of the American Association for Cancer Research (AACR), were made in cell culture and mice studies, but are so promising that

The new institute will focus on major brain and mind disorders including stroke, epilepsy, multiple sclerosis, dementia, Parkinson’s disease, addiction, schizophrenia and mood disorders. As part of the

Erbitux is already licensed in 53 countries for metastatic colorectal cancer after failure of irinotecan-based chemotherapy. With the European Commission’s approval, Erbitux will be available for the treatment

According to the company, Zestra is the only consumer product available that is clinically shown to quickly increase female sexual sensation, arousal, pleasure, and improve sexual experiences for

This phase I, dose-escalation trial of GRN163L is primarily designed to demonstrate the safety and tolerability of GRN163L administered intravenously (IV) on a weekly basis in patients with

The second phase III trial will involve approximately 630 patients in a randomized, double-blind multi-centre trial comparing Urocidin to bacillus calmette-guerin (BCG) as first-line therapy in non-muscle invasive

This new formulation, Actoplus met XR, would allow for once-daily dosing. The immediate release formulation of the drug is already being marketed by Takeda Pharmaceuticals North America. Actoplus